Therapeutics against filovirus infection

Current Topics in Microbiology and Immunology

Volumn 411, Issue , 2017, Pages 263-290

  Connor, John ^a   Kobinger, Gary ^b   Olinger, Gene ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; VIRUS RNA; ANTIVIRUS AGENT;

CLINICAL STUDY; CONVALESCENCE; DISEASE MODEL; EBOLAVIRUS; EPIDEMIC; FILOVIRUS INFECTION; GENE TARGETING; HUMAN; LIFE CYCLE; NONHUMAN; PLASMA; PRECLINICAL STUDY; PRIORITY JOURNAL; VIRUS ATTACHMENT; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS REPLICATION; VIRUS TRANSCRIPTION; CLINICAL TRIAL (TOPIC); PROCEDURES; VIROLOGY;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE OUTBREAKS; FILOVIRIDAE INFECTIONS; HUMANS;

EID: 85039451249     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/82_2017_12     Document Type: Chapter

References (109)

1. Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, Adegnika AA, Altfeld M, Auderset F, Bache EB, Biedenkopf N, Borregaard S, Brosnahan JS, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling SK, Finckh A, Goncalves AR, Grobusch MP, Hooper J, Jambrecina A, Kabwende AL, Kaya G, Kimani D, Lell B, Lemaitre B, Lohse AW, Massinga-Loembe M, Matthey A, Mordmuller B, Nolting A, Ogwang C, Ramharter M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl FR, Staines HM, Strecker T, Stubbe HC, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kieny MP, Bejon P, Kremsner PG, Addo MM, Siegrist CA (2016) Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. New Engl J Med 374(17):1647–1660. doi:10.1056/NEJMoa1502924.
2. Aman MJ (2016) Chasing Ebola through the Endosomal Labyrinth. MBio 7(2), e00346. doi:10.1128/mBio.00346-16.
3. Bai CQ, Mu JS, Kargbo D, Song YB, Niu WK, Nie WM, Kanu A, Liu WW, Wang YP, Dafae F, Yan T, Hu Y, Deng YQ, Lu HJ, Yang F, Zhang XG, Sun Y, Cao YX, Su HX, Sun Y, Liu WS, Wang CY, Qian J, Liu L, Wang H, Tong YG, Liu ZY, Chen YS, Wang HQ, Kargbo B, Gao GF, Jiang JF (2016) Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone 2014. Clin Infect Dis: Official publication Infect Dis Soc Am 63(10):1288–1294. doi:10.1093/cid/ciw571.
4. Basu A, Mills DM, Mitchell D, Ndungo E, Williams JD, Herbert AS, Dye JM, Moir DT, Chandran K, Patterson JL, Rong L, Bowlin TL (2015) Novel Small Molecule Entry Inhibitors of Ebola Virus. J Infect Dis 212(Suppl 2):425–434. doi:10.1093/infdis/jiv223.
5. Borisevich IV, Mikhailov VV, Krasnianskii VP, Gradoboev VN, Lebedinskaia EV, Potryvaeva NV, Timan’kova GD (1995) Development and study of the properties of immunoglobulin against Ebola fever. Vopr Virusol 40(6):270–273.
6. Borisevich IV, Mikhailov VV, Potryvaeva NV, Malinkin IuN, Kirillov AP, Krasnianskii VP, Markov VI, Makhlai AA, Lebedinskaia EV (1996) Development of the immunoenzyme test-system for detection of Ebola virus antigen. Vopr Virusol 41(5):232–234.
7. Borisevich IV, Potryvaeva NV, Mel’nikov SA, Evseev AA, Krasnianskii VP, Maksimov VA (2008) Design of equine serum-based Marburg virus immunoglobulin. Vopr Virusol 53(1):39–41.
8. Brainard J, Hooper L, Pond K, Edmunds K, Hunter PR (2016a) Risk factors for transmission of Ebola or Marburg virus disease: a systematic review and meta-analysis. Int J Epidemiol 45(1):102–116. doi:10.1093/ije/dyv307.
9. Brainard J, Pond K, Hooper L, Edmunds K, Hunter P (2016b) Presence and persistence of ebola or marburg virus in patients and survivors: a rapid systematic review. PLoS Neglected Tropical Dis 10(2):e0004475. doi:10.1371/journal.pntd.0004475.
10. Butler D (2008) Gabon centre refocuses on emerging diseases. Nature 455(7217), 1156–1157. doi:10.1038/4551156b.
11. Cardile AP, Downey LG, Wiseman PD, Warren TK, Bavari S (2016a) Antiviral therapeutics for the treatment of Ebola virus infection. Curr Opin Pharmacol 30:138–143. doi:10.1016/j.coph.2016.08.016.
12. Cardile AP, Warren TK, Martins KA, Reisler RB, Bavari S (2016b) Will there be a cure for Ebola? Annu Rev Pharmacol Toxicol. doi:10.1146/annurev-pharmtox-010716-105055.
13. Casadevall A, Scharff MD (1995) Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis Official Publication Infect Dis Soc Am 21(1):150–161.
14. Cheng H, Lear-Rooney CM, Johansen L, Varhegyi E, Chen ZW, Olinger GG, Rong L (2015) Inhibition of Ebola and Marburg virus entry by G Protein-coupled receptor Antagonists. J Virol 89(19):9932–9938. doi:10.1128/jvi.01337-15.
15. Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Sprecher A (2014) Ebola virus disease in West Africa–clinical manifestations and management. New Engl J Med 371(22):2054–2057. doi:10.1056/NEJMp1413084.
16. Cohen J, Enserink M (2016) Infectious Disease. As Ebola epidemic draws to a close, a thin scientific harvest. Science 351(6268):12–13. doi:10.1126/science.351.6268.12.
17. Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose NA, Staupe RP, Bailey M, Shi W, Choe M, Marcus H, Thompson EA, Cagigi A, Silacci C, Fernandez-Rodriguez B, Perez L, Sallusto F, Vanzetta F, Agatic G, Cameroni E, Kisalu N, Gordon I, Ledgerwood JE, Mascola JR, Graham BS, Muyembe-Tamfun JJ, Trefry JC, Lanzavecchia A, Sullivan NJ (2016) Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351(6279):1339–1342. doi:10.1126/science.aad5224.
18. Cote M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, Hensley L, Li Q, Ory D, Chandran K, Cunningham J (2011) Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477(7364):344–348. doi:10.1038/nature10380.
19. Dowall S, Taylor I, Yeates P, Smith L, Rule A, Easterbrook L, Bruce C, Cook N, Corbin-Lickfett K, Empig C, Schlunegger K, Graham V, Dennis M, Hewson R (2013) Catheterized guinea pigs infected with Ebola Zaire virus allows safer sequential sampling to determine the pharmacokinetic profile of a phosphatidylserine-targeting monoclonal antibody. Antiviral Res 97(2):108–111. doi:10.1016/j.antiviral.2012.11.003.
20. Dowall SD, Bosworth A, Rayner E, Taylor I, Landon J, Cameron I, Coxon R, Al Abdulla I, Graham VA, Hall G, Kobinger G, Hewson R, Carroll MW (2016) Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic. Sci Rep 6:30497. doi:10.1038/srep30497.
21. Dowall SD, Graham VA, Corbin-Lickfett K, Empig C, Schlunegger K, Bruce CB, Easterbrook L, Hewson R (2015) Effective binding of a phosphatidylserine-targeting antibody to Ebola virus infected cells and purified virions. J Immunol Res 2015:347903. doi:10.1155/2015/347903.
22. Dunning J, Kennedy SB, Antierens A, Whitehead J, Ciglenecki I, Carson G, Kanapathipillai R, Castle L, Howell-Jones R, Pardinaz-Solis R, Grove J, Scott J, Lang T, Olliaro P, Horby PW (2016a) Experimental treatment of ebola virus disease with Brincidofovir. PLoS ONE 11(9):e0162199. doi:10.1371/journal.pone.0162199.
23. Dunning J, Sahr F, Rojek A, Gannon F, Carson G, Idriss B, Massaquoi T, Gandi R, Joseph S, Osman HK, Brooks TJ, Simpson AJ, Goodfellow I, Thorne L, Arias A, Merson L, Castle L, Howell-Jones R, Pardinaz-Solis R, Hope-Gill B, Ferri M, Grove J, Kowalski M, Stepniewska K, Lang T, Whitehead J, Olliaro P, Samai M, Horby PW (2016b) Experimental treatment of Ebola virus disease with TKM-130803: a Single-Arm Phase 2 Clinical Trial. PLoS Med 13(4):e1001997. doi:10.1371/journal.pmed.1001997.
24. Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE, Ortiz RA, Prugar LI, Pratt WD (2012) Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA 109(13):5034–5039. doi:10.1073/pnas.1200409109.
25. Dye JM, Wu H, Hooper JW, Khurana S, Kuehne AI, Coyle EM, Ortiz RA, Fuentes S, Herbert AS, Golding H, Bakken RA, Brannan JM, Kwilas SA, Sullivan EJ, Luke TC, Smith G, Glenn G, Li W, Ye L, Yang C, Compans RW, Tripp RA, Jiao JA (2016) Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle. Sci Rep 6:24897. doi:10.1038/srep24897.
26. Emond RT, Evans B, Bowen ET, Lloyd G (1977) A case of Ebola virus infection. BMJ 2(6086):541–544.
27. Enria D, Fernandez N, Briggiler A, Levis S, Maiztegui J (1984) Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. The Lancet 324(8397):255–256.
28. Feldmann HSa, Geisbert TW (2013) Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM (eds) Fields Firology, 6th edn. Lippincott Williams and Wilkins, Philadelphia, pp 923–956.
29. Filone CM, Hodges EN, Honeyman B, Bushkin GG, Boyd K, Platt A, Ni F, Strom K, Hensley L, Snyder JK, Connor JH (2013) Identification of a broad-spectrum inhibitor of viral RNA synthesis: validation of a prototype virus-based approach. Chem Biol 20(3):424–433. doi:10.1016/j.chembiol.2013.02.011.
30. Fusco ML, Hashiguchi T, Cassan R, Biggins JE, Murin CD, Warfield KL, Li S, Holtsberg FW, Shulenin S, Vu H, Olinger GG, Kim DH, Whaley KJ, Zeitlin L, Ward AB, Nykiforuk C, Aman MJ, Berry JD, Saphire EO (2015) Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs. PLoS Pathog 11(6):e1005016. doi:10.1371/journal.ppat.1005016.
31. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, Young HA, Fredeking TM, Rote WE, Vlasuk GP (2003a) Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362(9400):1953–1958. doi:10.1016/s0140-6736(03)15012-x.
32. Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-DiCaprio K, Fritz EA, Jahrling PB, McClintock K, Phelps JR, Lee AC, Judge A, Jeffs LB, MacLachlan I (2006) Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis 193(12):1650–1657. doi:10.1086/504267.
33. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I (2010) Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375(9729):1896–1905. doi:10.1016/s0140-6736(10)60357-1.
34. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE (2003b) Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 188(11):1618–1629. doi:10.1086/379724.
35. Gerber DE, Spigel DR, Giorgadze D, Shtivelband M, Ponomarova OV, Shan JS, Menander KB, Belani CP (2016) Docetaxel combined With Bavituximab in previously treated, advanced Nonsquamous non-small-cell lung Cancer. Clin Lung Cancer 17(3):169–176. doi:10.1016/j.cllc.2016.02.003.
36. Glisic S, Paessler S, Veljkovic N, Perovic VR, Prljic J, Veljkovic V (2015) Improving attrition rates in Ebola virus drug discovery. Expert Opin Drug Discov 10(9), 1025–1032. doi:10.1517/17460441.2015.1062872.
37. Group PIW, Multi-National PIIST (2016) A randomized, controlled trial of ZMapp for Ebola virus infection. New Engl J Med 375(15):1448–1456. doi:10.1056/NEJMoa1604330.
38. Haque A, Hober D, Blondiaux J (2015) Addressing therapeutic options for ebola virus infection in current and future outbreaks. Antimicrob Agents Chemot 59(10), 5892-5902. doi:10.1128/Aac.01105-15.
39. Hensley LE, Stevens EL, Yan SB, Geisbert JB, Macias WL, Larsen T, Daddario-DiCaprio KM, Cassell GH, Jahrling PB, Geisbert TW (2007) Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis 196(Suppl 2):390–399. doi:10.1086/520598.
40. Hiatt A, Pauly M, Whaley K, Qiu X, Kobinger G, Zeitlin L (2015) The emergence of antibody therapies for Ebola. Hum Antibodies 23(3–4), 49–56. doi:10.3233/HAB-150284.
41. Hill-Batorski L, Halfmann P, Neumann G, Kawaoka Y (2013) The cytoprotective enzyme heme oxygenase-1 suppresses Ebola virus replication. J Virol 87(24):13795–13802. doi:10.1128/jvi.02422-13.
42. Holtsberg FW, Shulenin S, Vu H, Howell KA, Patel SJ, Gunn B, Karim M, Lai JR, Frei JC, Nyakatura EK, Zeitlin L, Douglas R, Fusco ML, Froude JW, Saphire EO, Herbert AS, Wirchnianski AS, Lear-Rooney CM, Alter G, Dye JM, Glass PJ, Warfield KL, Aman MJ (2015) Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses. J Virol 90(1):266–278. doi:10.1128/JVI.02171-15.
43. Hunt L, Gupta-Wright A, Simms V, Tamba F, Knott V, Tamba K, Heisenberg-Mansaray S, Tamba E, Sheriff A, Conteh S, Smith T, Tobin S, Brooks T, Houlihan C, Cummings R, Fletcher T (2015) Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect Dis 15(11):1292–1299. doi:10.1016/S1473-3099(15)00144-9.
44. Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, Kaya G et al (2015) The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 15(10):1156–1166. doi:10.1016/S1473-3099(15)00154-1.
45. Jacobs M, Aarons E, Bhagani S, Buchanan R, Cropley I, Hopkins S, Lester R, Martin D, Marshall N, Mepham S, Warren S, Rodger A (2015) Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers. Lancet Infect Dis 15(11):1300–1304. doi:10.1016/s1473-3099(15)00228-5.
46. Jahrling PB, Frame JD, Rhoderick JB, Monson MH (1985) Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans R Soc Trop Med Hyg 79(3):380–384.
47. Jahrling PB, Geisbert J, Swearengen JR, Jaax GP, Lewis T, Huggins JW, Schmidt JJ, LeDuc JW, Peters CJ (1996) Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl 11:135–140.
48. Jahrling PB, Peters CJ (1984) Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain. Infect Immun 44(2):528–533.
49. Jahrling PB, Geisbert JB, Swearengen JR, Larsen T, Geisbert TW (2007) Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 196(2), S400–3. doi:10.1086/520587.
50. Jin J, Simmons G (2016) Inhibitory antibodies targeting emerging viruses: advancements and mechanisms. Clin Vaccine Immunol 23(7), 535–539. doi:10.1128/CVI.00136-16.
51. Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, Hoffstrom BG, Dewald LE, Schornberg KL, Scully C, Lehar J, Hensley LE, White JM, Olinger GG (2013) FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med 5 (190):190ra179. doi:10.1126/scitranslmed.3005471.
52. Johansen LM, DeWald LE, Shoemaker CJ, Hoffstrom BG, Lear-Rooney CM, Stossel A, Nelson E, Delos SE, Simmons JA, Grenier JM, Pierce LT, Pajouhesh H, Lehar J, Hensley LE, Glass PJ, White JM, Olinger GG (2015) A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. Sci Transl Med 7 (290):290ra289. doi:10.1126/scitranslmed.aaa5597.
53. Johnson JC, Martinez O, Honko AN, Hensley LE, Olinger GG, Basler CF (2014) Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells. Antiviral Res 107:102–109. doi:10.1016/j.antiviral.2014.04.014.
54. Krasnianskii BP, Mikhailov VV, Borisevich IV, Gradoboev VN, Evseev AA, Pshenichnov VA (1995) Preparation of hyperimmune horse serum against Ebola virus. Vopr Virusol 40(3):138–140.
55. Krasnianskii VP, Mikhailov VV, Borisevich IV, Gradoboev VN, Evseev AA, Pshenichnov VA (1994) The isolation of hyperimmune horse serum to the Ebola virus. Vopr Virusol 39(2):91–92.
56. Kudoyarova-Zubavichene NM, Sergeyev NN, Chepurnov AA, Netesov SV (1999) Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J Infect Dis 179(Suppl 1):218–223. doi:10.1086/514294.
57. Kugelman JR, Kugelman-Tonos J, Ladner JT, Pettit J, Keeton CM, Nagle ER, Garcia KY, Froude JW, Kuehne AI, Kuhn JH, Bavari S, Zeitlin L, Dye JM, Olinger GG, Sanchez-Lockhart M, Palacios GF (2015) Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail. Cell reports 12(12):2111–2120. doi:10.1016/j.celrep.2015.08.038.
58. Larsen T, Stevens EL, Davis KJ, Geisbert JB, Daddario-DiCaprio KM, Jahrling PB, Hensley LE, Geisbert TW (2007) Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virus. J Infect Dis 196(Suppl 2):323–328. doi:10.1086/520589.
59. Leligdowicz A, Fischer WA, 2nd Uyeki TM, Fletcher TE, Adhikari NK, Portella G, Lamontagne F, Clement C, Jacob ST, Rubinson L, Vanderschuren A, Hajek J, Murthy S, Ferri M, Crozier I, Ibrahima E, Lamah MC, Schieffelin JS, Brett-Major D, Bausch DG, Shindo N, Chan AK, O’Dempsey T, Mishra S, Jacobs M, Dickson S, Lyon GM 3rd, Fowler RA (2016) Ebola virus disease and critical illness. Crit Care 20(1), 217. doi:10.1186/s13054-016-1325-2.
60. Liddell AM, Davey RT Jr, Mehta AK, Varkey JB, Kraft CS, Tseggay GK, Badidi O, Faust AC, Brown KV, Suffredini AF, Barrett K, Wolcott MJ, Marconi VC, Lyon GM 3rd, Weinstein GL, Weinmeister K, Sutton S, Hazbun M, Albarino CG, Reed Z, Cannon D, Stroher U, Feldman M, Ribner BS, Lane HC, Fauci AS, Uyeki TM (2015) Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United States. Ann Intern Med 163(2):81–90. doi:10.7326/M15-0530.
61. Madelain V, Nguyen TH, Olivo A, de Lamballerie X, Guedj J, Taburet AM, Mentre F (2016) Ebola virus infection: review of the Pharmacokinetic and Pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clin Pharmacokinet 55(8):907–923. doi:10.1007/s40262-015-0364-1.
62. Markin VA, Mikhailov VV, Krasnianskii VP, Borisevich IV, Firsova IV (1997) Developing principles for emergency prevention and treatment of Ebola fever. Vopr Virusol 42(1):31–34.
63. Mattia JG, Vandy MJ, Chang JC, Platt DE, Dierberg K, Bausch DG, Brooks T, Conteh S, Crozier I, Fowler RA, Kamara AP, Kang C, Mahadevan S, Mansaray Y, Marcell L, McKay G, O’Dempsey T, Parris V, Pinto R, Rangel A, Salam AP, Shantha J, Wolfman V, Yeh S, Chan AK, Mishra S (2016) Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. Lancet Infect Dis 16(3), 331–338. doi:10.1016/S1473-3099(15)00489-2.
64. McCarthy SD, Majchrzak-Kita B, Racine T, Kozlowski HN, Baker DP, Hoenen T, Kobinger GP, Fish EN, Branch DR (2016) A Rapid Screening Assay Identifies Monotherapy with Interferon-ss and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus. PLoS Negl Trop Dis 10(1):e0004364. doi:10.1371/journal.pntd.0004364.
65. McMullan LK, Flint M, Dyall J, Albarino C, Olinger GG, Foster S, Sethna P, Hensley LE, Nichol ST, Lanier ER, Spiropoulou CF (2016) The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus. Antiviral Res 125:71–78. doi:10.1016/j.antiviral.2015.10.010.
66. Mikhailov VV, Borisevich IV, Chernikova NK, Potryvaeva NV, Krasnianskii VP (1994) The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever. Vopr Virusol 39(2):82–84.
67. Mire CE, Geisbert JB, Agans KN, Thi EP, Lee AC, Fenton KA, Geisbert TW (2016) Passive Immunotherapy: assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates. J Infect Dis 214(Suppl 3):S367–S374. doi:10.1093/infdis/jiw333.
68. Misasi J, Chandran K, Yang JY, Considine B, Filone CM, Cote M, Sullivan N, Fabozzi G, Hensley L, Cunningham J (2012) Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences. J Virol 86(6):3284–3292. doi:10.1128/jvi.06346-11.
69. Moekotte AL, Huson MA, van der Ende AJ, Agnandji ST, Huizenga E, Goorhuis A, Grobusch MP (2016) Monoclonal antibodies for the treatment of Ebola virus disease. Expert Opin Investig Drugs 25(11), 1325-1335. doi:10.1080/13543784.2016.1240785.
70. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M, Colebunders R, Muyembe-Tamfum JJ (1999) Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 179(Suppl 1):S18–23. doi:10.1086/514298.
71. Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz-Fontela C, Gunther S (2014) Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 105:17–21. doi:10.1016/j.antiviral.2014.02.014.
72. Olinger GG Jr, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly M, Whaley KJ, Lear CM, Biggins JE, Scully C, Hensley L, Zeitlin L (2012) Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA 109(44):18030–18035. doi:10.1073/pnas.1213709109.
73. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR (2002) Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 76(12):6408–6412.
74. Pattabhi S, Wilkins CR, Dong R, Knoll ML, Posakony J, Kaiser S, Mire CE, Wang ML, Ireton RC, Geisbert TW, Bedard KM, Iadonato SP, Loo YM, Gale M Jr. (2016) Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway. J Virol 90(5):2372–2387. doi:10.1128/jvi.02202-15.
75. Pecheur EI, Borisevich V, Halfmann P, Morrey JD, Smee DF, Prichard M, Mire CE, Kawaoka Y, Geisbert TW, Polyak SJ (2016) The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses. J Virol 90(6):3086–3092. doi:10.1128/jvi.02077-15.
76. Pettitt J, Zeitlin L, Kim DH, Working C, Johnson JC, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly MH, Whaley KJ, Ingram MF, Zovanyi A, Heinrich M, Piper A, Zelko J, Olinger GG (2013) Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Science translational medicine 5 (199):199ra113. doi:10.1126/scitranslmed.3006608.
77. Qiu X, Audet J, Wong G, Pillet S, Bello A, Cabral T, Strong JE, Plummer F, Corbett CR, Alimonti JB, Kobinger GP (2012a) Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Science translational medicine 4 (138):138ra181. doi:10.1126/scitranslmed.3003876.
78. Qiu X, Fernando L, Melito PL, Audet J, Feldmann H, Kobinger G, Alimonti JB, Jones SM (2012b) Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS neglected tropical diseases 6(3):e1575. doi:10.1371/journal.pntd.0001575.
79. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP (2014) Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514(7520):47–53. doi:10.1038/nature13777.
80. Rasmussen AL, Okumura A, Ferris MT, Green R, Feldmann F, Kelly SM, Scott DP, Safronetz D, Haddock E, LaCasse R, Thomas MJ, Sova P, Carter VS, Weiss JM, Miller DR, Shaw GD, Korth MJ, Heise MT, Baric RS, de Villena FP, Feldmann H, Katze MG (2014) Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance. Sci 346(6212), 987–991. doi:10.1126/science.1259595.
81. Rhein BA, Powers LS, Rogers K, Anantpadma M, Singh BK, Sakurai Y, Bair T, Miller-Hunt C, Sinn P, Davey RA, Monick MM, Maury W (2015) Interferon-gamma Inhibits Ebola Virus Infection. PLoS Pathog 11(11):e1005263. doi:10.1371/journal.ppat.1005263.
82. Richardson T, Johnston AM, Draper H (2017) A systematic review of Ebola treatment trials to assess the extent to which they adhere to ethical guidelines. PLoS One 12(1), e0168975. doi:10.1371/journal.pone.0168975.
83. Russek-Cohen E, Rubin D, Price D, Sun W, Cox E, Borio L (2016) A US Food and Drug Administration perspective on evaluating medical products for Ebola. Clinical trials 13(1):105–109. doi:10.1177/1740774515620613.
84. Saeed MF, Kolokoltsov AA, Freiberg AN, Holbrook MR, Davey RA (2008) Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus. PLoS Pathog 4(8):e1000141. doi:10.1371/journal.ppat.1000141.
85. Sandrittez T (1999) Palivizumab for respiratory syncytial virus prophylaxis. J Pediatr Health Care 13 (4):191–195; quiz 196–197. doi:10.1016/S0891-5245(99)90039-1.
86. Sissoko D, Keita M, Diallo B, Aliabadi N, Fitter DL, Dahl BA, Bore JA, Koundouno FR, Singethan K, Meisel S, Enkirch T, Mazzarelli A, Amburgey V, Faye O, Sall AA, Magassouba N, Carroll MW, Anglaret X, Malvy D, Formenty P, Aylward RB, Keita S, Djingarey MH, Loman NJ, Gunther S, Duraffour S (2016a) Ebola virus persistence in breast milk after no reported illness: a likely source of virus transmission from mother to child. Clin Infect Dis Official Publication Infect Dis Soc Am. doi:10.1093/cid/ciw793.
87. Sissoko D, Laouenan C, Folkesson E, M’lebing AB, Beavogui AH, Laouenan S, Carazo S et al (2016b) Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med 13(3):e1001967. doi:10.1371/journal.pmed.1001967.
88. Smith DR, McCarthy S, Chrovian A, Olinger G, Stossel A, Geisbert TW, Hensley LE, Connor JH (2010) Inhibition of heat-shock protein 90 reduces Ebola virus replication. Antiviral Res 87(2):187–194. doi:10.1016/j.antiviral.2010.04.015.
89. Smith LM, Hensley LE, Geisbert TW, Johnson J, Stossel A, Honko A, Yen JY, Geisbert J, Paragas J, Fritz E, Olinger G, Young HA, Rubins KH, Karp CL (2013) Interferon-beta therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis 208(2), 310–318. doi:10.1093/infdis/jis921.
90. Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS (2014) Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res 104:153–155. doi:10.1016/j.antiviral.2014.01.012.
91. Soares MM, King SW, Thorpe PE (2008) Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med 14(12):1357–1362. doi:10.1038/nm.1885.
92. Sobarzo A, Ochayon DE, Lutwama JJ, Balinandi S, Guttman O, Marks RS, Kuehne AI, Dye JM, Yavelsky V, Lewis EC, Lobel L (2013) Persistent immune responses after Ebola virus infection. The New England journal of medicine 369(5):492–493. doi:10.1056/NEJMc1300266.
93. Sueblinvong V, Johnson DW, Weinstein GL, Connor MJ Jr, Crozier I, Liddell AM, Franch HA, Wall BR, Kalil AC, Feldman M, Lisco SJ, Sevransky JE (2015) Critical care for multiple organ failure secondary to Ebola virus disease in the United States. Crit Care Med 43(10):2066–2075. doi:10.1097/CCM.0000000000001197.
94. Swenson DL, Warfield KL, Warren TK, Lovejoy C, Hassinger JN, Ruthel G, Blouch RE, Moulton HM, Weller DD, Iversen PL, Bavari S (2009) Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob Agents Chemother 53(5):2089–2099. doi:10.1128/aac.00936-08.
95. Thi EP, Mire CE, Lee AC, Geisbert JB, Zhou JZ, Agans KN, Snead NM, Deer DJ, Barnard TR, Fenton KA, MacLachlan I, Geisbert TW (2015) Lipid Nanoparticle siRNA Treatment Ebola-Virus-Makona-Infected Nonhuman Primates. Nature 521(7552):362–365. doi:10.1038/nature14442.
96. Thorpe PE (2010) Targeting anionic phospholipids on tumor blood vessels and tumor cells. Thromb Res 125(Suppl 2):134–137. doi:10.1016/S0049-3848(10)70031-1.
97. van Griensven J, Edwards T, Baize S, Ebola-Tx C (2016a) Efficacy of Convalescent Plasma in Relation to Dose of Ebola Virus Antibodies. New Engl J Med 375(23):2307–2309. doi:10.1056/NEJMc1609116.
98. van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, Horby PW, Raoul H, Magassouba N, Antierens A, Lomas C, Faye O, Sall AA, Fransen K, Buyze J, Ravinetto R, Tiberghien P, Claeys Y, De Crop M, Lynen L, Bah EI, Smith PG, Delamou A, De Weggheleire A, Haba N, Ebola-Tx C (2016b) Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. New Engl J Med 374(1):33–42. doi:10.1056/NEJMoa1511812.
99. van Griensven J, Edwards T, Gallian P, Ebola-Tx C (2016c) Convalescent Plasma for Ebola Virus Disease. New Engl J Med 374(25):2500. doi:10.1056/NEJMc1602284.
100. Warfield KL, Swenson DL, Olinger GG, Nichols DK, Pratt WD, Blouch R, Stein DA, Aman MJ, Iversen PL, Bavari S (2006) Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog 2(1):e1. doi:10.1371/journal.ppat.0020001.
101. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, Braun MR, Flint M, McMullan LK, Chen SS, Fearns R, Swaminathan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, Cihlar T, Bavari S (2016) Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531(7594):381–385. doi:10.1038/nature17180.
102. Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA, Garza NL, Dong L, Mourich DV, Crumley S, Nichols DK, Iversen PL, Bavari S (2010) Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 16(9):991–994. doi:10.1038/nm.2202.
103. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G, Honnold S, Bantia S, Kotian P, Chen X, Taubenheim BR, Welch LS, Minning DM, Babu YS, Sheridan WP, Bavari S (2014) Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508(7496):402–405. doi:10.1038/nature13027.
104. Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, Bharrhan S, Kuehne AI, Bornholdt ZA, Flyak AI, Saphire EO, Crowe JE Jr, Aman MJ, Dye JM, Lai JR, Chandran K (2016) A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses. Science 354(6310):350–354. doi:10.1126/science.aag3267.
105. Wong G, Qiu X, de La Vega MA, Fernando L, Wei H, Bello A, Fausther-Bovendo H, Audet J, Kroeker A, Kozak R, Tran K, He S, Tierney K, Soule G, Moffat E, Gunther S, Gao GF, Strong J, Embury-Hyatt C, Kobinger G (2016) Pathogenicity Comparison Between the Kikwit and Makona Ebola Virus Variants in Rhesus Macaques. J Infect Dis 214(Suppl 3):S281–S289. doi:10.1093/infdis/jiw267.
106. Xu Z, Jin B, Teng G, Rong Y, Sun L, Zhang J, Du N, Liu L, Su H, Yuan Y, Chen H (2016) Epidemiologic characteristics, clinical manifestations, and risk factors of 139 patients with Ebola virus disease in western Sierra Leone. Am J Infect Control 44(11), 1285–1290. doi:10.1016/j.ajic.2016.04.216.
107. Yen HL (2016) Current and novel antiviral strategies for influenza infection. Curr Opin Virol 18:126–134. doi:10.1016/j.coviro.2016.05.004.
108. Zhao Y, Ren J, Harlos K, Jones DM, Zeltina A, Bowden TA, Padilla-Parra S, Fry EE, Stuart DI (2016) Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature 535(7610):169–172. doi:10.1038/nature18615.
109. Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R Jr, Nunneley JW, Barnard D, Pohlmann S, McKerrow JH, Renslo AR, Simmons G (2015) Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res 116:76–84. doi:10.1016/j.antiviral.2015.01.011.